CURRENT RESEARCH PROJECTS
THE GRAIL – Tissue in Host Engineering Guided Regeneration of Arterial Intimal Layer
Type: Partnered research project – EU Grant nr. 278557
Partners: The THE GRAIL consortium – Project Coordinator: Explora Biotech (IT)
The THEGRAIL project aims at developing bioactive and bioresorbable scaffolds that locally regenerates intima growth in patients with atherosclerosis. Within the framework of the THEGRAIL project, Explora will act as coordinator, leveraging its expertise to design and test in vivo the novel scaffold. The project explores an unexplored area arterial obstruction therapy: the substitution of the diseased arterial intima with an absorbable bioactive scaffold, called the synthesized intimal layer (SIL), is meant to be repopulated by resident and circulating patient’s cells”. Indeed, SIL does not intend to stent the artery; conversely it aims to replace the diseased and stiffened area with a soft and compliant intelligent scaffold that becomes reabsorbed once its task is completed, leaving a physiologically responsive regenerated tissue. For any inquiry, please contact us info@explora-biotech.com or www.thegrail-project.eu
NEXT – Nano Engineering for Cross Tolerance
Type: Partnered research project – EU Grant nr. 602235
Partners: The NEXT consortium – Project Coordinator: Explora Biotech (IT)
The Nano Engineering for Cross Tolerance: new approach for bioengineered, vascularised, chimeric islet transplantation in non-immunosuppressed hosts (NEXT) project aims at developing the next generation of chimeric pancreatic islet for diabetes 1 treatment. NEXT will provide a 360° solution to the pitfalls of current methodology for pancreatic islet transplantation:
i) Nano technologies, to engineer donor cell surfaces in order to derange recognition and suppress their rejection;
ii) Advanced tissue engineering methods, to assemble bio synthetic islet, enriched by chimeric microvasculature;
iii) Innovative double immune-suppressive strategy using immunosuppressive nano peptides
For any inquiry, please contact us info@explora-biotech.com or www.thenext-project.eu
AMCARE – Advanced Materials for Cardiac Regeneration
Type: Partnered research project – EU Grant nr. 604531
Partners: The AMCARE consortium – Project Coordinator: RCSI (IR)
AMCARE develops regenerative therapies which aim to circumvent some of the limitations of current treatments for MI patients. Our rationale is to use biomaterials to deliver cells or growth factors to the heart.
For any inquiry, please contact us info@explora-biotech.com or http://www.amcare.eu/
DRIVE – Diabetes reversing implant
Type: Partnered research project – EU Grant nr. 645991
Partners: The DRIVE consortium – Project Coordinator: RCSI (IR)
DRIVE aims to improve pancreatic islet transplant therapy for diabetes mellitus, a chronic disease characterised by high blood sugar due to a shortage of insulin. Transplant of insulin-producing pancreatic islets restores tight natural control of blood sugar, eliminating the need for multiple daily injections of insulin, that ultimately affect patient’s quality of life.
For any inquiry, please contact us info@explora-biotech.com or http://www.drive-project.eu/
LIAR- Living Architetture
Type: Partnered research project – EU Grant nr. 686585
Partners: The LIAR consortium – Project Coordinator: Univ. Newcaslte (UK)
LIAR objective is to design and build a proof-of-concept ‘LIving ARchitecture’ which targeted breakthrough is to build a ‘living brick’ that hosts a synthetic microbial consortium capable of turning waste into resources (e.g. “polished” water, recoverable phosphate and etergents, electricity). Within the framework of LIAR, EXPLORA will leverage its competence in synthetic and system biology to support the design and fabrication of the first prototype of living brick.
For any inquiry, please contact us info@explora-biotech.com or http://www.livingarchitecture-h2020.eu
COMPLETED RESEARCH PROJECTS
Explora has a long track of records in international and trans-natinal research and development. Below is a list of some of our past proprietary project that reach the market.
ETOILE – Bioethanol Production via lignocellulosic fermentation of olive oil residues
Type: Partnered research project – EU Grant nr. 222331
Partners: The ETOILE consortium – Project Coordinator: Labor Srl (IT)
The ETOILE project developed a new integrated process for simultaneous saccharification fermentation of olive oil wastes to produce ethanol. Within the framework of theETOILE project, EXPLORA developed a purification process to isolate cellulase enzymes from olive mill waste water. These enzymes can then be used onto the solid olive oil residues, such as olive pulp and husks, to obtain ethanol. The enzyme mix has been outlicenced to BIOTECGEN for the south europe market. For any inquiry, please contact us info@explora-biotech.com
MAGISTER – Magnetic Scaffold for Tissue Engineering
Type: Partnered research project – EU Grant nr. 214685-2
Partners: The MAGISTER consortium – Project Coordinator: National Research Counsil – ISMN (IT)
The project aimed at developing a highly porous bioactive scaffolds for tissue engineering exploiting paramagnetic materials for advanced clinical applications with a special emphasis on the angiogenesis process (www.magister-project.eu). Within the MAGISTER project, Explora will leverage its expertise in protein engineering and optimization to develop novel bioconjugatin protocols to reduce sample inter-batch variability for GMP production. The experitise acquired within the MAGISTER project is now the techinical basis for EXPLORA’s protein labeling service
BOLALIP – Bola lipids for oral and systemic drug delivery
Type: Partnered research project – Israel-Italy Joint Innovation Programm
Partners: National Reseach Counsil (IT), Hebrew University Jerusalem (IL) and BioLab Ltd (IL)
The BOLALip project developed a novel drug delivery system exploiting the unique chemico-physical properties of synthetic bipolar lipids (Bolalipids). Lipid based (liposomes, emulsions, micelles and other lipid assemblies) drug delivery systems (DDS), while proved successful for parental applications fail in most oral applications due to chemical and physical stability issues of drug delivery systems based on conventional lipids in the GastroIntestinal (GI) tract. Replacing conventional lipids (mainly phospholipids) with Bolalipids may help to overcome these major obstacles. Within the framework of the BOLALIP project, Explora designed and implemented a biosynthetic pathways for the synthesis of functionalised isoprenic hydrocarbon chains which constitute the backbone of bolalipids (PMID:26592865). For any inquiry, please contact us info@explora-biotech.com
Are you interested in a partnered research program? Contact our Business Development Office, we will be pleased to provide you with any information you may require